The pharmaceutical industry needs more innovation in bioprocesses

Future Medicinal Chemistry

Volumn 3, Issue 14, 2011, Pages 1737-1740

  Kircher, Manfred ^a  

^a Cluster Industrielle Biotechnologie EV CLIB2021 ^*  (Germany)

Author keywords

biology; biotherapeutics; chemical industry; enzymatic catalysis; fermentation; pharmaceutical industry; product recovery; production cost; synthetic

Indexed keywords

ECULIZUMAB;

BIOCATALYST; BIOPROCESS; BIOREACTOR; CATALYSIS; COMMERCIAL PHENOMENA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DECOMPOSITION; DRUG INDUSTRY; DRUG PURIFICATION; ESCHERICHIA COLI; FINANCIAL MANAGEMENT; HUMAN; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PRODUCT RECOVERY; REIMBURSEMENT; REVIEW; SYNTHETIC BIOLOGY;

BIOCATALYSIS; DRUG INDUSTRY; FERMENTATION; ORGANIZATIONAL INNOVATION;

EID: 80054929700     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.124     Document Type: Review

References (6)

1. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: the pharmaceuticals industry grand challenge. Nature Rev. Drug Discov. 9, 203-214 (2010)
2. Light DW, Warburton R. Drug R&D costs questioned. Genetic Eng. Biotechnol. News 31(13), 1 (2011).
3. Mullard A. 2010 FDA drug approvals. Nature Rev. Drug Discov. 10, 82-85 (2011).
4. Conway R. USA Biobased products market potential & projections through 2025. USDA Report 720-166, February (2008).
5. Maheshwari SH. Booming US Generic drug market. RNCOS Report, 1-60, March (2011). www. rncos.com/Report/IM589.htm
6. Burrill St. Biotech 2011: 25 years looking back to see ahead. Burrill & Company, 2-0 (2011). www.burrillandco.com/resources-66-0-0- 462-Biotech-2011-Life-Sciences-Looking- Back-to-See-Ahead-PRINT.html